
Auteur O. H. GRIFFIN III
|
Documents disponibles écrits par cet auteur (4)

L. LEBAN ; O. H. GRIFFIN III | 2020
Dans Journal of Substance Use (Vol.25, n°6, November 2020) Article : PériodiqueBackground: Drug policies aimed at youth often adopt "scare tactics" approaches, which highlight harms of substances to dissuade youth from using them. However, the success of deterrent approaches remains widely debated, and some scholars have c[...]
Various concerns and rationales have been the driving force for drug regulation in the United States. The Controlled Substances Act of 1970 (CSA) set up a comprehensive list of schedules and criteria that were intended to guide how all drugs wer[...]
O. H. GRIFFIN III ; J. F. SPILLANE | 2013
Dans Journal of Drug Issues (Vol.43, n°2, April 2013) Article : PériodiqueOxyContin, a controlled-release opioid developed and produced by Purdue Pharma, was given Food and Drug Administration (FDA) approval in December 1995. By 1999, to the apparent surprise of Purdue Pharma, the Drug Enforcement Administration (DEA)[...]
J. STOGNER ; D. N. KHEY ; O. H. GRIFFIN III ; B. L. MILLER ; J. H., IV BOMAN | 2012
Dans International Journal of Drug Policy (Vol.23, n°6, November 2012) Article : PériodiqueBackground: A plant with dissociative and psychoactive properties began to attract the attention of the media and United States policymakers following a well-publicized suicide in 2006 and reports that the plant served as a 'legal high' and subs[...]